Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
PGR heads into its October 14 earnings report with analyst targets moving higher, options mildly cautious, and the lending market utterly uninterested in taking the other side.
The most actionable signal this week is the analyst tape. Barclays raised its target to $247 on October 7, keeping an Overweight rating. JP Morgan followed on October 5, lifting to $250 from $241 while staying at Neutral. The Street's mean target is $232.71 against a current price of $212.05, implying roughly 10% upside. The direction of travel is clearly upward: Keefe Bruyette upgraded to Outperform back in late August with a $250 target, and even the firms holding Neutral or Underweight ratings have been edging their numbers higher. Wells Fargo, the lone Underweight, raised its target to $201, while Cantor has a $200 Neutral. The debate is less about direction and more about the degree of upside. Bulls point to Progressive's position as America's second-largest personal auto insurer with 27 million policies and its discipline around maintaining profitable growth. Bears flag slower premium growth, a rising core loss ratio, and competitive pressures as rivals finish pushing through their own rate increases.
Positioning in the lending market says very little about conviction. Short interest in PGR is just 1.1% of the free float, around 6.6 million shares, an amount that has drifted up 5.5% over the past week and 10% over the past month. Those are meaningful percentage moves on a thin base, not evidence of a meaningful bear campaign building. Borrow costs confirm the same read: at 0.36%, cost to borrow has actually fallen 17% on the week and 27% over the past month, the cheapest borrowing conditions of the period covered here. Availability is about as loose as it gets, with the lending pool nowhere near constrained. The ORTEX short score of 30 sits in the 76th percentile for utilization rank, but the absolute numbers do not support a short-squeeze narrative. Options are mildly tilted toward puts, with the put/call ratio at 0.90 versus a 20-day average of 0.88, a z-score of just 0.54. That is within normal range and well below the 52-week high of 1.08. Pre-earnings hedging is present but not aggressive.
Valuation multiples are in the mid-range for an insurer of this quality. The trailing P/E is 12.6 times, down roughly 0.4 points over the past month, while price-to-book is 3.1 times. EV/EBITDA is near 7.6. The factor profile shows a strong dividend score at the 85th percentile, a reasonable EPS surprise rank at 68, and short score rank at 76, but EPS momentum tells a more cautious story. The 30-day EPS momentum score is in the 8th percentile, and the 90-day reading is in the 13th. Forward earnings revisions have been soft, with the 12-month forward growth estimate in deeply negative territory. That gap between the positive near-term analyst target moves and the weak momentum in earnings revision trends is the central tension heading into next week's print.
Insider activity adds texture without changing the core story. Every trade in the recent record is a sale under a pre-arranged 10b5-1 plan: CEO Susan Griffith sold 37,338 shares for roughly $8.2 million on September 1, and CFO Andrew Quigg sold $770,000 worth in late July. The CIO, the Claims President, the Commercial Lines President, and the Chief Personal Lines Officer all executed plan-driven sales over the same period. Net insider activity totalled negative $23.2 million over the past 90 days. Pre-arranged sales are compensation mechanics rather than bearish conviction, but the absence of any open-market buying across the executive suite is worth noting at a stock trading below its recent high of around $220. Institutional holders are stable, with BlackRock at 8.3% and Capital Research at 8.1% as the largest positions, and FMR added 3.4 million shares in the quarter to September.
Wikipedia traffic for PGR posted a z-score of 2.1 against the prior 90 days, suggesting a notable pickup in retail attention toward late September. With earnings seven days out, the October 14 print is the natural next focal point: the question is whether the improving analyst target trajectory reflects a real change in the loss-ratio trend, or whether early signs of normalisation in personal auto claims will prove more challenging than the Overweight consensus expects.
See the live data behind this article on ORTEX.
Open PGR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
